Rhythm Pharma to Acquire Global Rights to Oral MC4R Agonist

 Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced it has entered into a global licensing agreement with LG Chem, Ltd. ("LG Chem"), a leading global company headquartered in South Korea that specializes in life sciences as one of its core businesses, for LB54640, an investigational oral small molecule melanocortin-4 receptor (MC4R) agonist now in Phase 2 clinical trials.

https://www.globenewswire.com/news-release/2024/01/04/2803835/0/en/Rhythm-Pharmaceuticals-and-LG-Chem-Life-Sciences-Enter-Agreement-for-Rhythm-to-Acquire-Global-Rights-to-Oral-MC4R-Agonist-LB54640.html